TY - JOUR
T1 - Effectiveness of active nasal surveillance culture for Methicillin-resistant Staphylococcus aureus in patients undergoing colorectal surgery
AU - Kondo, Takayuki
AU - Okabayashi, Koji
AU - Sugiura, Kiyoaki
AU - Obara, Hideaki
AU - Takeuchi, Hiroya
AU - Wada, Norihito
AU - Takano, Yaoko
AU - Iwata, Satoshi
AU - Hasegawa, Naoki
AU - Kitagawa, Yuko
N1 - Funding Information:
Koji Okabayashi reports grants from Taiho Oncology Inc, CHUGAI PHARMACEUTICAL CO., LTD., and Toray Industries, Inc. Kitagawa has received grants and personal fees from AsahiKASEI Co., Ltd., grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD, grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants from DAIICHI SANKYO COMPANY, LIMITED, grants from Merck Serono Co., Ltd., grants and personal fees from EA Pharma Co., Ltd., grants and personal fees from Yakult Honsha Co. Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Factory Inc., grants and personal fees from SHIONOGI & CO., LTD. , grants from KAKEN PHARMACEUTICAL CO.,LTD., grants from Kowa Pharmaceutical Co., Ltd., grants and personal fees from Astellas Pharma Inc., grants from MEDICON INC., grants and personal fees from DAINIPPON SUMITOMO PHARMA Co., Ltd., grants and personal fees from Taisho Toyama Pharmaceutical Co., Ltd., grants from Kyouwa Hakkou Kirin Co., Ltd., grants from Pfizer Japan Inc., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from NIHON PHARMACEUTICAL CO., LTD., grants from Japan Blood Products Organization, grants from Medtronic Japan Co., Ltd., grants and personal fees from Sanofi K.K., grants from Eisai Co., Ltd. , grants from TSUMURA & CO., grants from KCI Licensing, Inc., grants from ABBOTT JAPAN CO., LTD., grants from FUJIFILM Toyama Chemical Co., Ltd., outside the submitted work.
Publisher Copyright:
© 2020
PY - 2020/12
Y1 - 2020/12
N2 - Objective: The aim of this study was to clarify the role of Methicillin-resistant Staphylococcus aureus (MRSA) carriers in the development of surgical site infection (SSI) after colorectal surgery. Summary background data: MRSA is commonly implicated in hospital-acquired infections. Active surveillance culture (ASC) using the nasal swab test is useful to detect MRSA in surgical patients. We hypothesized that MRSA carriers would be more susceptible to SSI after colorectal surgery Methods: Patients who underwent ASC between 2010 and 2013 were included in this study. The incidence of SSI was compared between MRSA carriers and non-carriers using the chi-square test. The odds ratio for SSI was computed using logistic regression analyses. Results: Among 355 patients, 12 (3.4%) were identified as MRSA carriers and 343 as non-carriers. Of all the patients, 65 patients (18.3%) developed an SSI. Of these, 6 cases were in MRSA carriers and 59 cases were in non-carriers (p < 0.01). This meant that half of the 12 MRSA carriers developed an SSI, compared with only 17.2% of non-carriers (59 cases out of 343 patients). Therefore, MRSA carriers had a significantly higher risk of SSI (adjusted odds ratio = 4.77 [1.37 to 16.6], p = 0.01). Conclusions: Detection of MRSA via ASC is significantly associated with the development of SSI after colorectal surgery. These findings indicate that ASC for MRSA is useful to predict an SSI.
AB - Objective: The aim of this study was to clarify the role of Methicillin-resistant Staphylococcus aureus (MRSA) carriers in the development of surgical site infection (SSI) after colorectal surgery. Summary background data: MRSA is commonly implicated in hospital-acquired infections. Active surveillance culture (ASC) using the nasal swab test is useful to detect MRSA in surgical patients. We hypothesized that MRSA carriers would be more susceptible to SSI after colorectal surgery Methods: Patients who underwent ASC between 2010 and 2013 were included in this study. The incidence of SSI was compared between MRSA carriers and non-carriers using the chi-square test. The odds ratio for SSI was computed using logistic regression analyses. Results: Among 355 patients, 12 (3.4%) were identified as MRSA carriers and 343 as non-carriers. Of all the patients, 65 patients (18.3%) developed an SSI. Of these, 6 cases were in MRSA carriers and 59 cases were in non-carriers (p < 0.01). This meant that half of the 12 MRSA carriers developed an SSI, compared with only 17.2% of non-carriers (59 cases out of 343 patients). Therefore, MRSA carriers had a significantly higher risk of SSI (adjusted odds ratio = 4.77 [1.37 to 16.6], p = 0.01). Conclusions: Detection of MRSA via ASC is significantly associated with the development of SSI after colorectal surgery. These findings indicate that ASC for MRSA is useful to predict an SSI.
KW - Colorectal surgery
KW - Methicillin-resistant Staphylococcus aureus
KW - Surgical site infection
UR - http://www.scopus.com/inward/record.url?scp=85089883347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089883347&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2020.06.013
DO - 10.1016/j.jiac.2020.06.013
M3 - Article
C2 - 32861579
AN - SCOPUS:85089883347
SN - 1341-321X
VL - 26
SP - 1244
EP - 1248
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 12
ER -